1198784-97-2

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide, phosphoric acid is used as a potential pharmaceutical compound for [application reason]. The unique structure and combination of functional groups in (R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide, phosphoric acid may provide specific biological activities or interactions with biological targets, making it a candidate for further research and development in the pharmaceutical field.
Used in Chemical Synthesis:
In the chemical synthesis industry, (R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide, phosphoric acid can be used as a building block or intermediate for the synthesis of more complex molecules. Its diverse functional groups and structural features may enable the creation of novel compounds with various applications in different industries.
Used in Material Science:
The unique structure and properties of (R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide, phosphoric acid may also find applications in the field of material science. It could potentially be used in the development of new materials with specific properties, such as improved stability, reactivity, or selectivity in various chemical processes.

Upstream product

• 1198784-72-3 (R)-2-(4-((5-(ethylsulfonyl)-1H-pyrroio[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide 
• 1198785-57-7 (R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide anisole solvate 

Relevant academic research and scientific papers

Development of a large scale asymmetric synthesis of the glucocorticoid agonist BI 653048 BS H3PO4

The development of a large scale synthesis of the glucocorticoid agonist BI 653048 BS H3PO4 (1·H3PO4) is presented. A key trifluoromethyl ketone intermediate 22 containing an N-(4-methoxyphenyl)ethyl amide was prepared by an enolization/bromine-magnesium exchange/electrophile trapping reaction. A nonselective propargylation of trifluoromethyl ketone 22 gave the desired diastereomer in 32% yield and with dr = 98:2 from a 1:1 diastereomeric mixture after crystallization. Subsequently, an asymmetric propargylation was developed which provided the desired diastereomer in 4:1 diastereoselectivity and 75% yield with dr = 99:1 after crystallization. The azaindole moiety was efficiently installed by a one-pot cross coupling/indolization reaction. An efficient deprotection of the 4-methoxyphenethyl group was developed using H3PO4/anisole to produce the anisole solvate of the API in high yield and purity. The final form, a phosphoric acid cocrystal, was produced in high yield and purity and with consistent control of particle size.

PROCESS FOR OPTIMIZING THE PARTICLE SIZE OF AN ACTIVE PHARMACEUTICAL INGREDIENT BY CRYSTALLIZATION

A process to crystallize uniform small particles of a compound of Formula (I) with narrow particle size distribution and excellent powder characteristics that facilitate the formulation process and optimal drug product performance, wherein the compound of